Article in Mediators of inflammation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Yi WeiHepatobiliary Center, Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.ORCID https://orcid.org/0009-0001-6945-628X
Xinyu ZhanHepatobiliary Center, Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.ORCID https://orcid.org/0000-0002-1405-3301
Qingfa BuHepatobiliary Center, Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.ORCID https://orcid.org/0000-0002-6864-2160
Zibo XuHepatobiliary Center, Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.ORCID https://orcid.org/0009-0004-3202-6130
Xiaozhang XuHepatobiliary Center, Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.ORCID https://orcid.org/0000-0001-6756-8483
Qi WangHepatobiliary Center, Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.ORCID https://orcid.org/0000-0002-0349-9260
Yue YuHepatobiliary Center, Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.ORCID https://orcid.org/0000-0001-7457-6596
Haoming ZhouHepatobiliary Center, Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.ORCID https://orcid.org/0000-0003-2778-221X
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
ATG16L1 Depletion-Mediated Activation of the TRAF1 Signaling in Macrophages Aggravates Liver Fibrosis. · full record | OpenQuestion